摘要
目的探讨骨化三醇与普通维生素D3治疗原发性骨质疏松症的疗效。方法筛选出符合临床研究要求的90例骨质疏松症患者,随机分为3组。分别为:骨化三醇组30例,给予骨化三醇胶丸(罗盖全)0.5μg/日和阿仑膦酸钠(福善美)70 mg/周;普通维生素D3组30例,给予维生素D滴剂胶囊(普通维生素D3)800 IU/日和阿仑膦酸钠(福善美)70 mg/周;阿仑膦酸钠-维D3组30例,给予阿仑膦酸钠-维D3片(福美加)70 mg/5 600 IU/周;所有患者均给予碳酸钙片1.5 g/日(含元素钙600 mg)。分别于干预前及干预6个月后:测量腰椎及左髋骨密度(bone density,BMD),测定血清25羟基维生素D[25(OH)D]、1?25二羟基维生素D3[1?25(OH)2D3]含量。结果干预6个月后:三组腰椎和左髋BMD均升高,普通维生素D3组、阿仑膦酸钠-维D3组钙激素指标25(OH)D、1?25(OH)2D3均有所上升,骨化三醇组则下降,三组组内前后比较均有统计学意义(P<0.01)。普通维生素D3组、阿仑膦酸钠-维D3组腰椎及左髋BMD增加均优于骨化三醇组(P<0.05),普通维生素D3组与阿仑膦酸钠-维D3组组间无统计学差异(P>0.05)。普通维生素D3组、阿仑膦酸钠-维D3组25(OH)D、1?25(OH)2D3增加均优于骨化三醇组(P<0.05),普通维生素D3组与阿仑膦酸钠-维D3组组间无统计学差异(P>0.05)。结论普通维生素D3联合阿仑膦酸钠可提高骨质疏松合并维生素D不足患者BMD及25(OH)D、1,25(OH)2D3水平,疗效优于骨化三醇组,提示骨质疏松合并维生素D不足患者,适宜补充普通维生素D3治疗骨质疏松症。
Objective To investigate the efficacy of calcitriol and vitamin D3 in the treatment of primary osteoporosis. Methods 90 patients with osteoporosis were selected and randomly divided into three groups. 30 cases in the calcitriol group were given calcitriol capsules(Rogaiquan) 0.5 ug/day and alendronate sodium(Fushanmei) 70 mg/week;30 cases in the ordinary vitamin D3 group were given vitamin D drops capsules(ordinary vitamin D3) 800 IU/day and alendronate sodium(Fushanmei) 70 mg/week;30 cases in the alendronate sodium-vitamin D3 group were given alendronate sodium-vitamin D3 tablets(Fumeijia) 70 mg/5600 IU/week.All patients were given calcium carbonate tablets 1.5 g/day(containing 600 mg of elemental calcium). Before intervention and 6 months after intervention respectively,Bone density(BMD)of lumbar spine and left hip were measured,serum 25-hydroxyvitamin D 25(OH) D、 1?25-dihydroxyvitamin D3(1?25(OH)2D3) were determined. Results After 6 months of intervention, BMD of lumbar spine and left hip increased in all three groups, while calcium hormone indexes 25(OH) D and 1?25(OH)2D3 increased in the ordinary vitamin D3 group and in the alendronate sodium-vitamin D3 group, and decreased in the calcitriol group, with statistical difference before and after the three groups(P<0.01). BMD of lumbar spine and left hip in the ordinary vitamin D3 group and in the alendronate sodium-vitamin D3 group was higher than that in the calcitriol group(P<0.05). There was no significant difference between the ordinary vitamin D3 group and the alendronate sodium-vitamin D3 group(P>0.05). The increase of 25(OH) D and 1?25(OH)2D3 in the ordinary vitamin D3 group and in the alendronate sodium-vitamin D3 group were better than that in the calcitriol group(P<0.05). There was no significant difference between the ordinary vitamin D3 group and the alendronate sodium-vitamin D3 group(P>0.05). Conclusion Ordinary vitamin D3 combined with alendronate sodium may increase the level of BMD and 25(OH)D、1?25(OH)2D3 in patients with osteoporosis and v
作者
薛青
张礼超
周奕
XUE Qing;ZHANG Lichao;ZHOU Yi(The Fifth Affiliated Hospital of SunYat-sen University, Zhuhai 519000, China)
出处
《广州医药》
2019年第4期62-65,共4页
Guangzhou Medical Journal
